UK
Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
1 December 2021
Outcome-based payment (OBP) is a flexible payment mechanism linking the price the NHS pays for a medicine to the outcomes it achieves in practice for NHS…
After the Transplant: Potential Benefits for the NHS and UK Kidney Transplant Patients
1 November 2021
Around 10% of people in the United Kingdom (UK) have chronic kidney disease (CKD) according to Kidney Care UK. While CKD can be managed through diet and…
A Case Study Analysis: Challenges in the NICE Evaluation of Multi-Indication Medicines for Rare and Ultra-Rare Diseases
1 September 2021
Medicines for rare and ultra-rare conditions face distinct economic and ethical challenges compared to medicines for more common conditions. These challenges are implicitly acknowledged by the…
Realising The Broader Value of Vaccines in the UK: Ready for Prime Time?
1 February 2021
The COVID-19 pandemic has revealed the broad and devastating health, economic and societal impact of a highly infectious and deadly disease. In addition to the human…
Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?
1 February 2021
This research paper examines whether value of a life estimates used in economic evaluation differs between government departments in a selection of developed countries. The authors find that generally estimates used in transport and the environment exceeded those used in health, which suggests that health may be undervalued by departments of health compared to departments of transport or environment.
Realising the Broader Value of Vaccines in the UK
8 January 2020
Many health technology assessment (HTA) agencies limit their assessment of vaccines to individual health benefits and the costs associated with vaccine administration and the disease avoided.…
The Broader Value of Vaccines: The Return on Investment From a Governmental Perspective
1 August 2020
Most value assessments of vaccination programs are carried out by taking the perspective of the health system. To stimulate the debate concerning the broader value of vaccination beyond this perspective, this report quantifies the related return on investment to the UK government.
NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?
7 January 2020
The National Institute of Health and Care Excellence (NICE) makes recommendations for the use of interventions including medicines in the National Health Service in England based…
Delivering the 2.4 Percent: Unlocking UK Pharma R&D Investment through Evidence-Based Policies
1 June 2020
In the 2017 Industrial Strategy, the Government committed to increasing investment in UK Research and Development to the OECD-average of 2.4% of Gross Domestic Product (GDP)…